On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the shareholders of Abliva AB (publ) (“Abliva”) to tender all their shares in Abliva to Pharming at a price of SEK 0.45 in cash per share (the “Offer”). An offer document relating to the Offer was published on January 15, 2025.

Pharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET.

Pharming Group N.V. announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming’s new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.

Pharming Group N.V. today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva.

Pharming Group N.V. announces positive topline results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).

Pharming Group N.V. is pleased to welcome Inés Bernal as our new Chief People Officer (CPO) and member of the Executive Committee as of December 1, 2024.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of November:

Pharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2024.

Pharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.